# PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

> **NCT06135675** · PHASE1,PHASE2 · COMPLETED · sponsor: **TenNor Therapeutics (Suzhou) Limited** · enrollment: 36 (actual)

## Conditions studied

- Hyperammonemia

## Interventions

- **DRUG:** TNP-2092 capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06135675
- **Lead sponsor:** TenNor Therapeutics (Suzhou) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-27
- **Primary completion:** 2021-06-16
- **Final completion:** 2021-06-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06135675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06135675, "PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06135675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*